Why peptide merchants get shut down
If you sell research peptides and accept credit cards, your payment processor is the biggest operational risk to your business. Not your supplier. Not your shipping. Not your customer acquisition. Your processor. And the shutdown follows a predictable, devastating pattern that most merchants don't see coming until their funds are frozen.
A common shutdown sequence
Account terminations for peptide merchants often follow a recognizable pattern. Timing varies by acquirer, processor, chargeback exposure, and reserve policy:
Quick approval with minimal document review
Transaction volume grows as business gains traction
Automated flag — monitoring detects keywords or volume anomalies
Manual review — underwriter inspects website and transaction history
Termination or reserve action — account closed or restricted; funds may be held as a risk reserve
The process can move quickly from flag to funding hold when the merchant file, website claims, product catalog, descriptor, and transaction history do not line up.
Incorrect coding: the silent account killer
Correct merchant coding tells banks what you sell and helps determine your interchange fees, chargeback thresholds, and underwriting criteria.
Payment facilitators often misclassify peptide businesses to bypass underwriting restrictions. When that comes to light in an audit or monitoring review, the result can be termination and a reserve hold, often 90–180 days depending on dispute exposure and contract terms.
Beyond miscoding: other termination triggers
1. Marketing and claim violations
Processors scan merchant websites. Red flags include therapeutic claims ("promotes muscle growth"), before/after testimonials, dosing instructions, and social content promoting off-label use.
2. Chargeback ratio breaches
Visa and Mastercard monitoring thresholds vary, but merchants can enter monitoring around roughly 0.9–1.0% dispute ratios and face more severe programs at higher levels. Peptide merchants can exceed those levels if communication, fulfillment, billing descriptors, and refund handling are weak.
3. Inadequate compliance documentation
Underwriters commonly expect Certificates of Analysis for products, Terms of Service prohibiting human consumption, age verification where applicable, refund/shipping policies, and checkout acknowledgments confirming research-only intent.
4. Suspicious transaction patterns
Rapid volume spikes, high-ticket orders above historical averages, international sales in high-risk countries, and velocity anomalies all trigger fraud detection alerts.
The processor bait-and-switch
Some providers onboard peptide merchants without a durable acquiring-bank path. The merchant may process briefly, then face termination or reserves once monitoring catches the mismatch. Before signing, merchants should understand who the acquirer is, how the business is classified, what reserves apply, and what termination rights are in the agreement.
What legitimate peptide processing looks like
Properly underwritten peptide processing requires: detailed business application with ownership and product details, website compliance review, COA and supplier documentation verification, clear underwriting disclosures to the acquiring bank, and ongoing compliance monitoring. This is how ResearchPay operates — every merchant is fully disclosed to the acquiring bank from day one.